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1st Editorial Decision 19th Mar 2018 
Thank you for submitting your manuscript on the regulation of FGF21 levels through SEL1L-HRD1 
axis in mouse liver. We have now received three referee reports on your study, which are included 
below for your information.  
 
As you can see, while all referees consider the findings novel and interesting, referee #2 and #3 also 
raise some critical points that need to be addressed before they can support publication here.  
In particular, referees #2 is concerned that the study did not investigate the role of SEL1L in 
CREBH degradation, nor adequately test the kinetic of HRD1-dependent CREBH degradation. 
Referee #3 points out that the clarity of the manuscript would be greatly improved if you would edit 
and streamline the text incorporating his/her suggestions.  
 
Addressing these issues through additional data and altered presentation as suggested by the referees 
would be essential to warrant publication in The EMBO Journal. Given the overall interest of your 
study, I would thus like to invite you to revise the manuscript in response to the referee reports.  
 
 
REFEREE REPORTS: 
 
Referee #1:  
 
In their manuscript "Hepatic ER-Associated Degradation manages FGF21 levels and metabolism via 
CREBH during fasting-feeding and growth" Asmita Bhattacharya et. al. address the regulation of 
FGF21 via Sel1L-Hrd1 ERAD.  
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The phenotypic investigation of the liver specific Sel1L-knockout mouse exhibits a defect in growth 
and female fertility. To examine where this growth retardation of the Sel1LAlb mice originates the 
authors performed a transcriptomic analysis of the liver. They identified Fgf21 to be elevated in the 
Sel1LAlb mice in contrast to WT mice. They could confirm these elevated levels on mRNA as well 
as protein level. Through a comparison of genome-wide expression analysis in genes that are altered 
in Fgf21-overexpressing transgenic mice with the Sel1LAlb mice they were able to show that the 
Sel1LAlb mice phenocopy Fgf21-gain-of-function mice.  
The authors identified Crebh to be responsible for the high levels of Fgf21. They were able to show 
that Crebh is interacting with Hrd-1 and that it is stabilized upon inhibition of ERAD or the 
proteasome but not through inhibition of the lysosome. Therefore, they conclude that Crebh is an 
ERAD substrate. Through conditional liver knockdown of Crebh the authors were able to rescue the 
phenotypes of the Sel1LAlb mice such as growth retardation, Fgf21 protein levels and glucose 
uptake. Finally the authors were able to show that Fgf21 levels are tightly regulated via Sel1L 
dependent control of Crebh during fasting-feeding and growth.  
 
The data shown in this manuscript presents a new pathway to regulate the liver-derived, fasting-
induced hormone Fgf21 via the conserved ERAD branch Sel1L-Hrd1. This represents a new 
function of the ERAD pathway in metabolism as well as new way to control the hormone Fgf21. 
Therefore, this topic will attract the broad readership of EMBO J.  
 
 
 
Referee #2:  
 
This manuscripts reports the phenotype of mice with liver specific deletion of Sel1L. These mice are 
smaller and the females are infertile. Fgf21 mRNA and protein levels are increased. Indeed these 
mice share similar phenotype as Fgf21 transgenic mice. Knockdown of Fgf21 partially rescues some 
of the the defects. The authors then show that Crebh levels are increased in the liver of these mice. 
Crebh is an ER-anchored transcription factor, which is cleaved in the Golgi to release the active 
transcription factor for many genes including Fgf21. Crebh degradation is reduced in 293 cells 
lacking Hrd1. Finally knockdown of Crebh partially rescues some of the defects observed in these 
animals.  
 
Overall the study is interesting and provides useful information about the role of Sel1L in liver. 
However, some issues need to be addressed to clarify the results of the study.  
 
Major Concerns:  
 
Sel1L is not associated only with Hrd1. Surprisingly, the requirement for Sel1L in Crebh 
degradation is not addressed inthis study. Instead the authors try to show that Hrd1 is required for 
Crebh degradation. Since other transcription factors of this family have been reported to be Hrd1 
substrates, Crebh may well be a Hrd1 substrate. However, this does not address the role of Sel1L in 
this process.  
 
In addition, this reviewer is not able to find information for the HEK293 cells lines with Hrd1 
knockout using CRISPR cited in ref 25. Instead ref 25 describes a Sel1L CRISPR cell line. It is not 
clear why this Sel1L knockout cell line is not used. Specificity should be address by re-expressing 
Sel1L in these cells.  
 
The exposure for Fig 5a looking at the degradation of Crebh in Hrd1 knockout cells makes it 
difficult to compare the kinetics of degradation between WT and KO. The quantitation also does not 
seem to reflect the density shown in the blot. Pulse chase experiments will be better for direct 
comparision. The cycloheximide experiment is further complicated by formation of the cleaved 
fragment of Crebh. Since these experiments are performed with transfected Crebh, it will be more 
useful to compare a Crebh mutant that cannot be cleaved.  
 
In Fig 5b, the conditions for IP is too mild. This can be seen in the co-IP of Hrd1 with Crebh. This 
design is flawed as the Hrd1 associated with Crebh could account for the difference din 
ubiquitination. Stringent conditions should be used to strip off co-associated proteins for 
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uiquitination assays. Co-IP experiments may well require a less stringent buffer and should be part 
of a separate experiment.  
 
In Fig 6, knockdown of Crebh is partial. This results in a reduction in the levels of Fgf21, but the 
remaining levels are at least 10 fold over control. It is surprising that growth (as measured by weight 
gain) is fully restored in these animals and their blood glucose levels are almost indistinguishable 
from those of control animals.  
 
 
Referee #3:  
 
In the study entitled "Hepatic ER-Associated Degradation manages FGF21 levels and metabolism 
via CREBH during fasting-feeding and growth" Bhattacharya and colleagues discover that, in mice, 
the Sel1L-Hrd1 ERAD complex plays a crucial role in regulating Fgf21 transcription and growth in 
a Crebh-dependent manner. They first show that the Hrd1 and Sel1L protein levels in the liver 
fluctuate in response to growth and fasting-feeding. To further investigate the role of the hepatic 
Hrd1-Sel1L degradation axis in vivo, the authors use hepatocyte-specific Sel1L-deficient mice and 
find that these mice are growth retarded. Moreover, liver-specific Sel1L KO showed highly 
increased Fgf21 expression in the liver with concomitant increase of circulating Fgf21. Interestingly, 
it is shown that in many aspects this mice phenocopies Fgf21-transgenic mice. By further exploring 
the Sel1 Fgf21 connection, it is shown that the previously described short half-life of the 
transcription factor Crebh is due to the activity of Sel1L-Hrd1 complex and that intracellular Crebh 
accumulation in Sel1L KO leads to increased Fgf21. This was further confirmed by Crebh depletion 
experiments. Lastly, it is shown that the hepatic Sel1L-Hrd1 protein complex is dynamically 
regulated during growth and fasting-feeding and as such regulates the activity of the Crebh-Fgf21 
axis. Thus, this study identifies the Sel1L-Hrd1 ERAD complex as a key repressor of Fgf21 
transcription in the liver.  
 
This reviewer finds that throughout the study, experiments are well controlled and that most of the 
data is convincing. The findings are interesting and make valuable contributions to the field. 
However, there are some minor issues this reviewer would like to see resolved. Thus, I consider this 
work suitable for the audience of the EMBO Journal once the authors address the concerns raised 
below.  
 
Minor issues:  
Throughout the manuscript, the authors refer to Hrd1-Sel1L degradation axis using the term 
'ERAD'. Examples are the titles and text of first and last paragraph in the Results section. In this 
way, the authors give the impression that ERAD only consists of one axis, namely the Hrd1-Sel1L 
degradation complex. As the Hrd1-Sel1L axis is not the only axis in ERAD, the authors should be 
more specific in their phrasing.  
 
The authors state that Os9 is a substrate for the Hrd1-Sel1L degradation complex. While there is 
circumstantial evidence hinting that OS-9 may be degraded in a SEL1L/Hrd1-dependent manner, no 
published data exist (including the referenced paper) that convincingly shows that this is indeed the 
case.  
 
The immunofluorescence images in the manuscript should also show the single channels for clarity. 
Nuclear accumulation of Crebh is not obvious.  
 
Supplementary Figure 5 is critical to solidify the role of Fgf21 as main culprit in the Sel1L liver 
specific phenotypes. I would recommend the inclusion of (at least part of) the data in a main figure.  
 
Could the authors comment on why in some cases they observe a doublet for Crebh on Western blot, 
and in other cases is a singlet. Is this because different cell lines/types were used?  
 
In the final figure, the authors indicate that metabolic signals during fasting-feeding and growth 
influence the Hrd1-Sel1L degradation axis. While the data shown in figure 1 supports this, the 
authors do not discuss how these metabolic signals during fasting-feeding and growth might 
influence the Hrd1-Sel1L degradation axis, and what the identify of these metabolic signals might 
be.  
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In Figure 5A the authors forgot to add 'light' and 'dark' annotations for the two exposures shown.  
 
Typo in the second paragraph of the Discussion section. "Indeed, Crebh of Fgf32" should probably 
read "Indeed, Crebh or Fgf21". 
 
 
1st Revision - authors' response 15th Jul 2018 
Referee #1:  
 
In their manuscript "Hepatic ER-Associated Degradation manages FGF21 levels and metabolism via 
CREBH during fasting-feeding and growth" Asmita Bhattacharya et. al. address the regulation of 
FGF21 via Sel1L-Hrd1 ERAD.  
 
The phenotypic investigation of the liver specific Sel1L-knockout mouse exhibits a defect in growth 
and female fertility. To examine where this growth retardation of the Sel1LAlb mice originates the 
authors performed a transcriptomic analysis of the liver. They identified Fgf21 to be elevated in the 
Sel1LAlb mice in contrast to WT mice. They could confirm these elevated levels on mRNA as well 
as protein level. Through a comparison of genome-wide expression analysis in genes that are altered 
in Fgf21-overexpressing transgenic mice with the Sel1LAlb mice they were able to show that the 
Sel1LAlb mice phenocopy Fgf21-gain-of-function mice.  
The authors identified Crebh to be responsible for the high levels of Fgf21. They were able to show 
that Crebh is interacting with Hrd-1 and that it is stabilized upon inhibition of ERAD or the 
proteasome but not through inhibition of the lysosome. Therefore, they conclude that Crebh is an 
ERAD substrate. Through conditional liver knockdown of Crebh the authors were able to rescue the 
phenotypes of the Sel1LAlb mice such as growth retardation, Fgf21 protein levels and glucose 
uptake. Finally the authors were able to show that Fgf21 levels are tightly regulated via Sel1L 
dependent control of Crebh during fasting-feeding and growth.  
 
The data shown in this manuscript presents a new pathway to regulate the liver-derived, fasting-
induced hormone Fgf21 via the conserved ERAD branch Sel1L-Hrd1. This represents a new 
function of the ERAD pathway in metabolism as well as new way to control the hormone Fgf21. 
Therefore, this topic will attract the broad readership of EMBO J.  
 
We thank Referee #1 for their positive comments on our manuscript and deeply appreciate his/her 
support. 
 
 
Referee #2:  
 
This manuscripts reports the phenotype of mice with liver specific deletion of Sel1L. These mice are 
smaller and the females are infertile. Fgf21 mRNA and protein levels are increased. Indeed these 
mice share similar phenotype as Fgf21 transgenic mice. Knockdown of Fgf21 partially rescues some 
of the the defects. The authors then show that Crebh levels are increased in the liver of these mice. 
Crebh is an ER-anchored transcription factor, which is cleaved in the Golgi to release the active 
transcription factor for many genes including Fgf21. Crebh degradation is reduced in 293 cells 
lacking Hrd1. Finally knockdown of Crebh partially rescues some of the defects observed in these 
animals.  
 
Overall the study is interesting and provides useful information about the role of Sel1L in liver. 
However, some issues need to be addressed to clarify the results of the study.  
 
We thank Referee #2 for his/her insightful critique. Below we have detailed how we have addressed 
each of these concerns specifically in the revised manuscript. 
 
 
Major Concerns:  
 
Sel1L is not associated only with Hrd1. Surprisingly, the requirement for Sel1L in Crebh 
The EMBO Journal - Peer Review Process File 
 
 
© European Molecular Biology Organization 5 
degradation is not addressed in this study. Instead the authors try to show that Hrd1 is required for 
Crebh degradation. Since other transcription factors of this family have been reported to be Hrd1 
substrates, Crebh may well be a Hrd1 substrate. However, this does not address the role of Sel1L in 
this process. 
 
1. We now show that Sel1L CRISPR in human hepatocyte line Hep3B leads to Crebh 
accumulation and FGF21 induction (Figure 4J-K). Furthermore, we show here and in 
previous publications that Sel1L depletion leads to significant reduction of Hrd1 protein 
levels. Sel1L being a co-factor integral for Hrd1 stability and function, the specific function 
of Sel1L here is to facilitate the Hrd1-centered ERAD complex to target the ER-resident 
protein CREBH for proteasomal degradation. Whether Sel1L is involved in substrate 
recruitment remains an open question for the field. 
 
 
Left – Fig. 4J, 
Right – Fig. 4K:  
(4J-K) Western 
blot analysis of 
SEL1L, HRD1 and 
CREBH proteins 
(4J) and qPCR 
analysis of SEL1L, 
HRD1 and FGF21 
(4K) in human 
Hep3B 
hepatocytes upon CRISPR deletion of SEL1L with two different guides.  β-Actin, loading 
control for Western blot analysis.  Ribosomal L32, loading control for qPCR analysis.  
Values, mean ± SEM; *, p<0.05; **, p<0.01; ***, p<0.001; n.s., non-significant by 
Student’s t test. 
 
 
2. Additionally, new data from a co-IP experiment (Figure EV4F) now shows Sel1L to be 
pulled down with Crebh, further underscoring the interaction and importance of this protein 
in Crebh ERAD. 
 
In addition, this reviewer is not able to find information for the HEK293 cells lines with Hrd1 
knockout using CRISPR cited in ref 25. Instead ref 25 describes a Sel1L CRISPR cell line. It is not 
clear why this Sel1L knockout cell line is not used. Specificity should be address by re-expressing 
Sel1L in these cells.  
 
1. We have deleted the erroneous reference and included the correct reference for generation 
of the HRD1 knockout HEK293T cells in the methods section. HRD1-/- HEK293T cells 
have been previously described in PMID: 28920920, and Sel1L-/- and Hrd1-/- N2a cells 
have been previously described in PMID: 29457782. 
2. We have now included data showing Crebh stabilization in both Sel1L-/- and Hrd1-/- cells 
(Figure 5A and Figure EV4A-B), with the effect being much more pronounced in the 
Hrd1-/- cells, as Sel1L-/- cells presumably still retain residual Hrd1 activity. 
3. Upon over-expression of Sel1L, cells appeared very unhealthy and did not grow well. We 
suspect it could be due to altering the ratio between Hrd1 and Sel1L in these cells. Hence, 
we were unable to include this particular rescue experiment in this manuscript. However, as 
a whole, our data including several new pieces of data shown in Figure 4-5 is sufficient to 
support the notion that Sel1L-Hrd1 ERAD targets ER-resident CREBH for proteasomal 
degradation. 
 
The exposure for Fig 5a looking at the degradation of Crebh in Hrd1 knockout cells makes it 
difficult to compare the kinetics of degradation between WT and KO. The quantitation also does not 
seem to reflect the density shown in the blot. Pulse chase experiments will be better for direct 
comparison. The cycloheximide experiment is further complicated by formation of the cleaved 
fragment of Crebh. Since these experiments are performed with transfected Crebh, it will be more 
useful to compare a Crebh mutant that cannot be cleaved.  
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1. A new data is now shown in Figure 5A.   
2. We have tried the pulse-chase experiment for the last three months for CREBH. 
Unfortunately, our lab not being well set up for pulse chase analysis, we are facing 
technical challenges with carrying out a successful pulse chase experiment.  
3. To circumvent this issue, we now have generated a Crebh construct where the RNNNRNL 
of the S1P cleavage site and the LP of the S2P cleavage site have been mutated to Alanines. 
Using this and the Sel1L/Hrd1 CRISPR knockout cells, we have re-done our 
cycloheximide analysis to study and better delineate the half-life/stabilization of Crebh 
(Figure 5A and Figure EV4A-B). 
 
 
 
Left – Fig. 5A, Centre – Fig. EV4A, Right – Fig. EV4B:  (5A) Western blot analysis of 
Crebh protein half-life in transfected WT and HRD1-/- HEK293T cells treated with 
cycloheximide (CHX) for indicated times.  (EV4A-B) Western blot analysis of Crebh (A) 
and cleavage-defective-Crebh (B, Crebh*) half-life in transfected WT, Sel1L-/- and Hrd1-/- 
N2a cells treated with cycloheximide (CHX) for indicated times.  The decay of Crebh 
proteins are shown below each panel.  All cell culture experiments were done in 2-3 
independent repeats with cells passaged less than 3 times.  Hsp90, loading control for 
Western blot analysis. 
 
In Fig 5b, the conditions for IP is too mild. This can be seen in the co-IP of Hrd1 with Crebh. This 
design is flawed as the Hrd1 associated with Crebh could account for the difference in 
ubiquitination. Stringent conditions should be used to strip off co-associated proteins for 
ubiquitination assays. Co-IP experiments may well require a less stringent buffer and should be part 
of a separate experiment.  
 
1. We have now repeated the experiment with more stringent IP conditions (“Denaturing IP”) 
to strip off associated proteins. New data is now shown in Figure 5D and below, which 
demonstrates that CREBH is ubiquitinated in an Hrd1-dependent manner. We have also 
added co-IP data separately (Figure 5D under “Native IP” and EV4E-F) to show 
interaction between CREBH and Sel1L/Hrd1.  
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Left – Fig. 5D, 
Top right – Fig. 
EV4E, Bottom 
right – Fig. 
EV4F:  (5D) 
Western blot 
analysis of 
Crebh 
ubiquitination 
following 
immunoprecipit
ation of Crebh-
Flag and Crebh-
N-Flag in 
HEK293T cells 
transfected with 
indicated 
plasmids.  
Samples were 
boiled with 
SDS before IP 
for denaturing IP and not so for native IP.  These cells were treated with proteasomal inhibitor for 
the last 6 hrs prior to immunoprecipitation.  (EV4E-F) Co-immunoprecipitation analysis of Crebh 
with Hrd1 (E) and Sel1L (F) when co-expressed in HEK293T cells.  All cell culture experiments 
were done in 2-3 independent repeats with cells passaged less than 3 times.  Hsp90, loading control 
for Western blot analysis. 
 
 
 
In Fig 6, knockdown of Crebh is partial. This results in a reduction in the levels of Fgf21, but the 
remaining levels are at least 10 fold over control. It is surprising that growth (as measured by weight 
gain) is fully restored in these animals and their blood glucose levels are almost indistinguishable 
from those of control animals.  
 
1. We have now added more n number to the AAV-shCrebh (now n=10) experiment to make 
these experiments more reliable. With all the data taken together from all these mice 
(Figure EV5E and Figure 6E-F), the weight gain and ITT curves for these experiments 
show an intermediate pattern, suggestive of a partial rescue in response to the partial 
reduction in circulating Fgf21 levels in these mice. 
 
 
Left – Fig. EV5E, Centre – Fig. 6E, Right – Fig. 6F:  Data from the rescue experiments where 5-
week-old Sel1Lf/f and Sel1LAlb mice were injected i.v. with AAV8-shCrebh or control AAV8-shLuc.  
(EV5E) Weekly weight gain post injection (n=10 per group).  (6E) Weight gain 6 weeks post 
injection (n=10 per group).  (6F) Insulin tolerance test (ITT) 5-weeks after injection (n=10 per 
group).  Values, mean ± SEM; *, p<0.05; **, p<0.01; ***, p<0.001; n.s., non-significant by 2-way 
ANOVA analysis. 
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Referee #3:  
 
In the study entitled "Hepatic ER-Associated Degradation manages FGF21 levels and metabolism 
via CREBH during fasting-feeding and growth" Bhattacharya and colleagues discover that, in mice, 
the Sel1L-Hrd1 ERAD complex plays a crucial role in regulating Fgf21 transcription and growth in 
a Crebh-dependent manner. They first show that the Hrd1 and Sel1L protein levels in the liver 
fluctuate in response to growth and fasting-feeding. To further investigate the role of the hepatic 
Hrd1-Sel1L degradation axis in vivo, the authors use hepatocyte-specific Sel1L-deficient mice and 
find that these mice are growth retarded. Moreover, liver-specific Sel1L KO showed highly 
increased Fgf21 expression in the liver with concomitant increase of circulating Fgf21. Interestingly, 
it is shown that in many aspects this mice phenocopies Fgf21-transgenic mice. By further exploring 
the Sel1 Fgf21 connection, it is shown that the previously described short half-life of the 
transcription factor Crebh is due to the activity of Sel1L-Hrd1 complex and that intracellular Crebh 
accumulation in Sel1L KO leads to increased Fgf21. This was further confirmed by Crebh depletion 
experiments. Lastly, it is shown that the hepatic Sel1L-Hrd1 protein complex is dynamically 
regulated during growth and fasting-feeding and as such regulates the activity of the Crebh-Fgf21 
axis. Thus, this study identifies the Sel1L-Hrd1 ERAD complex as a key repressor of Fgf21 
transcription in the liver.  
 
This reviewer finds that throughout the study, experiments are well controlled and that most of the 
data is convincing. The findings are interesting and make valuable contributions to the field. 
However, there are some minor issues this reviewer would like to see resolved. Thus, I consider this 
work suitable for the audience of the EMBO Journal once the authors address the concerns raised 
below.  
 
We thank Referee #3 for his/her helpful comments on our manuscript. Below we have detailed how 
we have attempted to improve the discussion of specific parts of the manuscript as per these 
suggestions. 
 
Minor issues:  
Throughout the manuscript, the authors refer to Hrd1-Sel1L degradation axis using the term 
'ERAD'. Examples are the titles and text of first and last paragraph in the Results section. In this 
way, the authors give the impression that ERAD only consists of one axis, namely the Hrd1-Sel1L 
degradation complex. As the Hrd1-Sel1L axis is not the only axis in ERAD, the authors should be 
more specific in their phrasing.  
 
We agree with the reviewer’s comment here. We have now changed the title to reflect Sel1L-Hrd1 
ERAD, and edited our text to ensure more accurate and judicious use of the terms “Sel1L-Hrd1” and 
“ERAD” by referring specifically to Sel1L-Hrd1 ERAD except when discussing the ERAD 
machinery of the cell in general. 
 
The authors state that Os9 is a substrate for the Hrd1-Sel1L degradation complex. While there is 
circumstantial evidence hinting that OS-9 may be degraded in a SEL1L/Hrd1-dependent manner, no 
published data exist (including the referenced paper) that convincingly shows that this is indeed the 
case.  
 
We agree with the reviewer’s statement completely and have edited the manuscript to make our text 
more scientifically precise and correct. 
 
The immunofluorescence images in the manuscript should also show the single channels for clarity. 
Nuclear accumulation of Crebh is not obvious.  
 
We have now edited the figures to include single channel images for Crebh in the current data 
panels (Figure 4H and Figure EV3F). 
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Left – Fig. 4H, Rottom right – Fig. EV3F: Representative confocal images (4H) and zoomed out 
versions (EV3F) of Crebh in the liver cryosections of 8-week-old mice.  Note that a fraction of 
hepatocytes is binucleated.   
 
Supplementary Figure 5 is critical to solidify the role of Fgf21 as main culprit in the Sel1L liver 
specific phenotypes. I would recommend the inclusion of (at least part of) the data in a main figure. 
 
We have now moved some of the Fgf21-KD data to main Figure 2J-L and revised the text 
accordingly. 
 
Could the authors comment on why in some cases they observe a doublet for Crebh on Western blot, 
and in other cases is a singlet. Is this because different cell lines/types were used?  
 
This is likely due to the different gel running conditions (% of the gel and running time) as well as 
different cell types. Crebh is a protein with 4 glycosylation sites. We have noted different amounts 
of glycosylation in different cell types, leading to bands with different mobility on SDS-PAGE.  
 
In the final figure, the authors indicate that metabolic signals during fasting-feeding and growth 
influence the Hrd1-Sel1L degradation axis. While the data shown in figure 1 supports this, the 
authors do not discuss how these metabolic signals during fasting-feeding and growth might 
influence the Hrd1-Sel1L degradation axis, and what the identify of these metabolic signals might 
be.  
 
The reviewer made a great point. We have now discussed the point in the discussion on page 13, to 
highlight the openness and importance of this topic. 
 
In Figure 5A the authors forgot to add 'light' and 'dark' annotations for the two exposures shown.  
 
We have now edited the figure to correct this oversight. 
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Typo in the second paragraph of the Discussion section. "Indeed, Crebh of Fgf32" should probably 
read "Indeed, Crebh or Fgf21".  
 
We have now edited the text to correct this error. 
 
 
2nd Editorial Decision 7th Aug 2018 
Thank you for submitting a revised version of your manuscript. It has now been seen by the original 
referees whose comments are shown below.  
 
As you will see, while they find that the criticisms have been sufficiently addressed, referee #2 and 
referee#3 ask you to further discuss the effect of: i) Sel1L overexpression on cell death; and ii) Hrd1 
and Sel1L depletion on CREBH degradation. In addition, before we can officially accept the 
manuscript there are a few editorial issues concerning text and figures that I need you to address:  
 
 
REFEREE REPORTS: 
 
Referee #1:  
 
The authors thoroughly addressed the remaining critical questions/points raised by all reviewers; the 
manuscript provides a very strong contribution for EMBO J.  
 
 
Referee #2:  
 
The authors have greatly improved their manuscript and addressed my concerns. The authors noted 
that overexpression of Sel1L induced cell death, which complicated their experiment to rescue 
Sel1L knockout cells. This information is important and should be discussed in the text.  
 
 
Referee #3:  
 
The manuscript has been improved in this revised version and I would highly recommend its 
publication in the embo journal.  
 
I would just request the authors to add a line to comment on the fact that depletion of Hrd1 has a 
much stronger effect on CRBH degradation than depletion of Sel1l. The authors always mention 
Hrd1/Sel1L axis as if they had similar phenotypes but the magnitude of the effect appears 
susbstantially different 
 
 
2nd Revision - authors' response 8th Aug 2018 
Thank you for your kind decision. Here we wish to submit our revised manuscript titled “Hepatic 
Sel1L-Hrd1 ER-Associated Degradation manages FGF21 levels and systemic metabolism via 
CREBH”.  
 
In this revised version, we have added comments on two points raised by the reviewers 2 and 3: 
(i) cell survival issues regarding our current Sel1L overexpression system (on page 20 we added: An 
attempt to overexpress Sel1L in cells resulted in complications in cell survival, an issue currently 
under further investigation.) 
(ii) more pronounced substrate stabilization in Hrd1-KO cells as compared to Sel1L-KO systems [on 
page 10 we added: Notably, accumulation and stabilization of Crebh protein were more pronounced 
in HRD1-/- cells than in SEL1L-/- cells, potentially owing to the residual Hrd1 protein in SEL1L-/- 
cells (Figure 1C) (33).]  
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" common	  tests,	  such	  as	  t-­‐test	  (please	  specify	  whether	  paired	  vs.	  unpaired),	  simple	  χ2	  tests,	  Wilcoxon	  and	  Mann-­‐Whitney	  
tests,	  can	  be	  unambiguously	  identified	  by	  name	  only,	  but	  more	  complex	  techniques	  should	  be	  described	  in	  the	  methods	  
section;
" are	  tests	  one-­‐sided	  or	  two-­‐sided?
" are	  there	  adjustments	  for	  multiple	  comparisons?
" exact	  statistical	  test	  results,	  e.g.,	  P	  values	  =	  x	  but	  not	  P	  values	  <	  x;
" definition	  of	  ‘center	  values’	  as	  median	  or	  average;
" definition	  of	  error	  bars	  as	  s.d.	  or	  s.e.m.	  
1.a.	  How	  was	  the	  sample	  size	  chosen	  to	  ensure	  adequate	  power	  to	  detect	  a	  pre-­‐specified	  effect	  size?
1.b.	  For	  animal	  studies,	  include	  a	  statement	  about	  sample	  size	  estimate	  even	  if	  no	  statistical	  methods	  were	  used.
2.	  Describe	  inclusion/exclusion	  criteria	  if	  samples	  or	  animals	  were	  excluded	  from	  the	  analysis.	  Were	  the	  criteria	  pre-­‐
established?
3.	  Were	  any	  steps	  taken	  to	  minimize	  the	  effects	  of	  subjective	  bias	  when	  allocating	  animals/samples	  to	  treatment	  (e.g.	  
randomization	  procedure)?	  If	  yes,	  please	  describe.	  
For	  animal	  studies,	  include	  a	  statement	  about	  randomization	  even	  if	  no	  randomization	  was	  used.
4.a.	  Were	  any	  steps	  taken	  to	  minimize	  the	  effects	  of	  subjective	  bias	  during	  group	  allocation	  or/and	  when	  assessing	  results	  
(e.g.	  blinding	  of	  the	  investigator)?	  If	  yes	  please	  describe.
4.b.	  For	  animal	  studies,	  include	  a	  statement	  about	  blinding	  even	  if	  no	  blinding	  was	  done
5.	  For	  every	  figure,	  are	  statistical	  tests	  justified	  as	  appropriate?
Do	  the	  data	  meet	  the	  assumptions	  of	  the	  tests	  (e.g.,	  normal	  distribution)?	  Describe	  any	  methods	  used	  to	  assess	  it.
Is	  there	  an	  estimate	  of	  variation	  within	  each	  group	  of	  data?
Yes,	  as	  stated	  in	  each	  figure	  legend.
Student's	  t-­‐test	  and	  2-­‐way	  ANOVA,	  as	  appropriate.
Yes.
YOU	  MUST	  COMPLETE	  ALL	  CELLS	  WITH	  A	  PINK	  BACKGROUND	  #
Based	  on	  sample	  size	  formula	  of	  power	  analysis,	  N=8(CV)2[1+(1-­‐PC)2]/(PC)2,	  to	  reach	  the	  error	  
0.05,	  Power	  0.80,	  percentage	  change	  in	  means	  (PC)	  is	  20%,	  co-­‐efficient	  of	  variation	  (CV)	  is	  10	  ~	  
15%	  (varies	  between	  the	  experiments).
4-­‐6	  mice	  per	  group	  is	  the	  minimal	  number	  of	  animals	  to	  obtain	  statistical	  significance.	  We	  
routinely	  used	  a	  total	  of	  4-­‐10	  mice	  in	  each	  study	  to	  ensure	  adequate	  power.
No	  samples	  or	  animals	  were	  excluded	  from	  analyses.
Mice	  in	  each	  group	  were	  randomly	  chosen	  matching	  in	  the	  age,	  genotype	  and	  gender.	  
See	  above.
The	  investigators	  were	  not	  blinded	  during	  experiments	  and	  result	  assessment.
See	  above.
1.	  Data
the	  data	  were	  obtained	  and	  processed	  according	  to	  the	  field’s	  best	  practice	  and	  are	  presented	  to	  reflect	  the	  results	  of	  the	  
experiments	  in	  an	  accurate	  and	  unbiased	  manner.
figure	  panels	  include	  only	  data	  points,	  measurements	  or	  observations	  that	  can	  be	  compared	  to	  each	  other	  in	  a	  scientifically	  
meaningful	  way.
graphs	  include	  clearly	  labeled	  error	  bars	  for	  independent	  experiments	  and	  sample	  sizes.	  Unless	  justified,	  error	  bars	  should	  
not	  be	  shown	  for	  technical	  replicates.
if	  n<	  5,	  the	  individual	  data	  points	  from	  each	  experiment	  should	  be	  plotted	  and	  any	  statistical	  test	  employed	  should	  be	  
justified
the	  exact	  sample	  size	  (n)	  for	  each	  experimental	  group/condition,	  given	  as	  a	  number,	  not	  a	  range;
Each	  figure	  caption	  should	  contain	  the	  following	  information,	  for	  each	  panel	  where	  they	  are	  relevant:
2.	  Captions
The	  data	  shown	  in	  figures	  should	  satisfy	  the	  following	  conditions:
Source	  Data	  should	  be	  included	  to	  report	  the	  data	  underlying	  graphs.	  Please	  follow	  the	  guidelines	  set	  out	  in	  the	  author	  ship	  
guidelines	  on	  Data	  Presentation.
Please	  fill	  out	  these	  boxes	  #	  (Do	  not	  worry	  if	  you	  cannot	  see	  all	  your	  text	  once	  you	  press	  return)
a	  specification	  of	  the	  experimental	  system	  investigated	  (eg	  cell	  line,	  species	  name).
B-­‐	  Statistics	  and	  general	  methods
the	  assay(s)	  and	  method(s)	  used	  to	  carry	  out	  the	  reported	  observations	  and	  measurements	  
an	  explicit	  mention	  of	  the	  biological	  and	  chemical	  entity(ies)	  that	  are	  being	  measured.
an	  explicit	  mention	  of	  the	  biological	  and	  chemical	  entity(ies)	  that	  are	  altered/varied/perturbed	  in	  a	  controlled	  manner.
a	  statement	  of	  how	  many	  times	  the	  experiment	  shown	  was	  independently	  replicated	  in	  the	  laboratory.
Any	  descriptions	  too	  long	  for	  the	  figure	  legend	  should	  be	  included	  in	  the	  methods	  section	  and/or	  with	  the	  source	  data.
	  
In	  the	  pink	  boxes	  below,	  please	  ensure	  that	  the	  answers	  to	  the	  following	  questions	  are	  reported	  in	  the	  manuscript	  itself.	  
Every	  question	  should	  be	  answered.	  If	  the	  question	  is	  not	  relevant	  to	  your	  research,	  please	  write	  NA	  (non	  applicable).	  	  
We	  encourage	  you	  to	  include	  a	  specific	  subsection	  in	  the	  methods	  section	  for	  statistics,	  reagents,	  animal	  models	  and	  human	  
subjects.	  	  
definitions	  of	  statistical	  methods	  and	  measures:
a	  description	  of	  the	  sample	  collection	  allowing	  the	  reader	  to	  understand	  whether	  the	  samples	  represent	  technical	  or	  
biological	  replicates	  (including	  how	  many	  animals,	  litters,	  cultures,	  etc.).
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This	  checklist	  is	  used	  to	  ensure	  good	  reporting	  standards	  and	  to	  improve	  the	  reproducibility	  of	  published	  results.	  These	  guidelines	  are	  
consistent	  with	  the	  Principles	  and	  Guidelines	  for	  Reporting	  Preclinical	  Research	  issued	  by	  the	  NIH	  in	  2014.	  Please	  follow	  the	  journal’s	  
authorship	  guidelines	  in	  preparing	  your	  manuscript.	  	  
PLEASE	  NOTE	  THAT	  THIS	  CHECKLIST	  WILL	  BE	  PUBLISHED	  ALONGSIDE	  YOUR	  PAPER
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Is	  the	  variance	  similar	  between	  the	  groups	  that	  are	  being	  statistically	  compared?
6.	  To	  show	  that	  antibodies	  were	  profiled	  for	  use	  in	  the	  system	  under	  study	  (assay	  and	  species),	  provide	  a	  citation,	  catalog	  
number	  and/or	  clone	  number,	  supplementary	  information	  or	  reference	  to	  an	  antibody	  validation	  profile.	  e.g.,	  
Antibodypedia	  (see	  link	  list	  at	  top	  right),	  1DegreeBio	  (see	  link	  list	  at	  top	  right).
7.	  Identify	  the	  source	  of	  cell	  lines	  and	  report	  if	  they	  were	  recently	  authenticated	  (e.g.,	  by	  STR	  profiling)	  and	  tested	  for	  
mycoplasma	  contamination.
*	  for	  all	  hyperlinks,	  please	  see	  the	  table	  at	  the	  top	  right	  of	  the	  document
8.	  Report	  species,	  strain,	  gender,	  age	  of	  animals	  and	  genetic	  modification	  status	  where	  applicable.	  Please	  detail	  housing	  
and	  husbandry	  conditions	  and	  the	  source	  of	  animals.
9.	  For	  experiments	  involving	  live	  vertebrates,	  include	  a	  statement	  of	  compliance	  with	  ethical	  regulations	  and	  identify	  the	  
committee(s)	  approving	  the	  experiments.
10.	  We	  recommend	  consulting	  the	  ARRIVE	  guidelines	  (see	  link	  list	  at	  top	  right)	  (PLoS	  Biol.	  8(6),	  e1000412,	  2010)	  to	  ensure	  
that	  other	  relevant	  aspects	  of	  animal	  studies	  are	  adequately	  reported.	  See	  author	  guidelines,	  under	  ‘Reporting	  
Guidelines’.	  See	  also:	  NIH	  (see	  link	  list	  at	  top	  right)	  and	  MRC	  (see	  link	  list	  at	  top	  right)	  recommendations.	  	  Please	  confirm	  
compliance.
11.	  Identify	  the	  committee(s)	  approving	  the	  study	  protocol.
12.	  Include	  a	  statement	  confirming	  that	  informed	  consent	  was	  obtained	  from	  all	  subjects	  and	  that	  the	  experiments	  
conformed	  to	  the	  principles	  set	  out	  in	  the	  WMA	  Declaration	  of	  Helsinki	  and	  the	  Department	  of	  Health	  and	  Human	  
Services	  Belmont	  Report.
13.	  For	  publication	  of	  patient	  photos,	  include	  a	  statement	  confirming	  that	  consent	  to	  publish	  was	  obtained.
14.	  Report	  any	  restrictions	  on	  the	  availability	  (and/or	  on	  the	  use)	  of	  human	  data	  or	  samples.
15.	  Report	  the	  clinical	  trial	  registration	  number	  (at	  ClinicalTrials.gov	  or	  equivalent),	  where	  applicable.
16.	  For	  phase	  II	  and	  III	  randomized	  controlled	  trials,	  please	  refer	  to	  the	  CONSORT	  flow	  diagram	  (see	  link	  list	  at	  top	  right)	  
and	  submit	  the	  CONSORT	  checklist	  (see	  link	  list	  at	  top	  right)	  with	  your	  submission.	  See	  author	  guidelines,	  under	  
‘Reporting	  Guidelines’.	  Please	  confirm	  you	  have	  submitted	  this	  list.
17.	  For	  tumor	  marker	  prognostic	  studies,	  we	  recommend	  that	  you	  follow	  the	  REMARK	  reporting	  guidelines	  (see	  link	  list	  at	  
top	  right).	  See	  author	  guidelines,	  under	  ‘Reporting	  Guidelines’.	  Please	  confirm	  you	  have	  followed	  these	  guidelines.
18:	  Provide	  a	  “Data	  Availability”	  section	  at	  the	  end	  of	  the	  Materials	  &	  Methods,	  listing	  the	  accession	  codes	  for	  data	  
generated	  in	  this	  study	  and	  deposited	  in	  a	  public	  database	  (e.g.	  RNA-­‐Seq	  data:	  Gene	  Expression	  Omnibus	  GSE39462,	  
Proteomics	  data:	  PRIDE	  PXD000208	  etc.)	  Please	  refer	  to	  our	  author	  guidelines	  for	  ‘Data	  Deposition’.
Data	  deposition	  in	  a	  public	  repository	  is	  mandatory	  for:	  
a.	  Protein,	  DNA	  and	  RNA	  sequences	  
b.	  Macromolecular	  structures	  
c.	  Crystallographic	  data	  for	  small	  molecules	  
d.	  Functional	  genomics	  data	  
e.	  Proteomics	  and	  molecular	  interactions
19.	  Deposition	  is	  strongly	  recommended	  for	  any	  datasets	  that	  are	  central	  and	  integral	  to	  the	  study;	  please	  consider	  the	  
journal’s	  data	  policy.	  If	  no	  structured	  public	  repository	  exists	  for	  a	  given	  data	  type,	  we	  encourage	  the	  provision	  of	  
datasets	  in	  the	  manuscript	  as	  a	  Supplementary	  Document	  (see	  author	  guidelines	  under	  ‘Expanded	  View’	  or	  in	  
unstructured	  repositories	  such	  as	  Dryad	  (see	  link	  list	  at	  top	  right)	  or	  Figshare	  (see	  link	  list	  at	  top	  right).
20.	  Access	  to	  human	  clinical	  and	  genomic	  datasets	  should	  be	  provided	  with	  as	  few	  restrictions	  as	  possible	  while	  
respecting	  ethical	  obligations	  to	  the	  patients	  and	  relevant	  medical	  and	  legal	  issues.	  If	  practically	  possible	  and	  compatible	  
with	  the	  individual	  consent	  agreement	  used	  in	  the	  study,	  such	  data	  should	  be	  deposited	  in	  one	  of	  the	  major	  public	  access-­‐
controlled	  repositories	  such	  as	  dbGAP	  (see	  link	  list	  at	  top	  right)	  or	  EGA	  (see	  link	  list	  at	  top	  right).
21.	  Computational	  models	  that	  are	  central	  and	  integral	  to	  a	  study	  should	  be	  shared	  without	  restrictions	  and	  provided	  in	  a	  
machine-­‐readable	  form.	  	  The	  relevant	  accession	  numbers	  or	  links	  should	  be	  provided.	  When	  possible,	  standardized	  
format	  (SBML,	  CellML)	  should	  be	  used	  instead	  of	  scripts	  (e.g.	  MATLAB).	  Authors	  are	  strongly	  encouraged	  to	  follow	  the	  
MIRIAM	  guidelines	  (see	  link	  list	  at	  top	  right)	  and	  deposit	  their	  model	  in	  a	  public	  database	  such	  as	  Biomodels	  (see	  link	  list	  
at	  top	  right)	  or	  JWS	  Online	  (see	  link	  list	  at	  top	  right).	  If	  computer	  source	  code	  is	  provided	  with	  the	  paper,	  it	  should	  be	  
deposited	  in	  a	  public	  repository	  or	  included	  in	  supplementary	  information.
22.	  Could	  your	  study	  fall	  under	  dual	  use	  research	  restrictions?	  Please	  check	  biosecurity	  documents	  (see	  link	  list	  at	  top	  
right)	  and	  list	  of	  select	  agents	  and	  toxins	  (APHIS/CDC)	  (see	  link	  list	  at	  top	  right).	  According	  to	  our	  biosecurity	  guidelines,	  
provide	  a	  statement	  only	  if	  it	  could.
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
The	  accession	  codes	  for	  microarray	  data	  will	  be	  made	  available	  for	  public	  via	  GEO	  database	  upon	  
acceptance	  of	  this	  manuscript.
Details	  of	  microarray	  are	  described	  in	  Materials	  and	  Methods	  section.
Yes.
All	  antibodies	  used	  have	  been	  described	  with	  company	  and	  catalog	  number	  in	  the	  Materials	  and	  
Methods	  section.
All	  cell	  lines	  sources	  are	  described	  in	  the	  Materials	  and	  Methods	  section	  with	  references.	  All	  cell	  
lines	  used	  were	  free	  of	  mycoplasma.
Mice	  were	  all	  of	  C57BL/6J	  background	  with	  genotypes	  as	  described	  in	  labels.	  Both	  males	  and	  
females	  were	  used.	  Mouse	  age	  information	  is	  indicated	  in	  	  legends.
All	  animal	  procedures	  were	  as	  per	  regulations	  by	  the	  Institutional	  Animal	  Care	  and	  Use	  Committee	  
of	  both	  Cornell	  University	  and	  University	  of	  Michigan	  Medical	  School.	  Further	  information	  
regarding	  the	  same	  is	  provided	  in	  Materials	  and	  Methods	  section.
The	  studies	  were	  in	  compliance	  with	  guidelines.
G-­‐	  Dual	  use	  research	  of	  concern
F-­‐	  Data	  Accessibility
C-­‐	  Reagents
D-­‐	  Animal	  Models
E-­‐	  Human	  Subjects
